Keryx Biopharmaceuticals, Inc.
(NASDAQ CM: KERX)
Attention investors who purchased shares of Keryx Biopharmaceuticals, Inc. before June 28, 2018:
Rigrodsky & Long is investigating potential claims against the board of directors of Keryx Biopharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Akebia Therapeutics, Inc. for approximately $1.3 billion.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (NASDAQ CM: KERX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Akebia Therapeutics, Inc. (“Akebia”) (NASDAQ GM: AKBA) in a transaction valued at approximately $1.3 billion. Under the terms of the agreement, shareholders of Keryx will receive 0.37433 common shares of Akebia for each share of Keryx they own.
If you own common stock of Keryx and purchased any shares before June 28, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware, Garden City, New York, and San Francisco, California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.